Brainscape's Knowledge GenomeTM


Top Flashcards (Certified)
All Flashcards

Chemotherapy > Anticancer > Flashcards

Anticancer Flashcards

1
Q

Adenocarcinomas

A

epithelial lining ducts. Lung, colon, breast, pancreas, stomach, oesophagus, prostate, ovary, endometrium

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Squamous cell cancers

A

Protective barrier epithelium. Skin, nasal cavity, larynx, lung, cervix, oesophagus

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Metastasis Rx

A

Chemotherapy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Invasive tumour treatment

A

resection with wide margin of non-malignant tissue.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Characteristics of normal cells versus malignant, transformed cells

A

NORMAL: growth in serum-containing medium. Contact inhibition. low density of growth. Require substratum/anchorage. ECM. Organised actin microfilaments. Flat. senescence on crisis. non tumorigenic. TRANSFORMED: grow in low/absent serum medium. no contact inhibition. high density growth. anchorage independent. little ECM. Disorganised microfilaments. rounded. immortal. indice tumours.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Properties of cancer

A

ESCAPE MECHANISMS OF REGULATION OF NORMAL GROWTH AND DIVISION. Evading apoptosis, sustained angiogenesis, no maximum replication, tissue invasion & metastasis, insensitive to anti-growth signals. self-sufficiency in growth signals.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Main target of cell cycle for cancer drugs

A

S phase when DNA is replicated. As G1 phase is when cells rest, it is variable in length and often is short in cancer cells most cells will be in S phase.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Epigenetic factors of cancer and what epigenetic is

A

Epigenetic = modifications in gene expression but no change in genome cause changes in phenotype of organism. E.g: Methylation of specific Cytosine in promoters or changes in chromatin structure independent of DNA.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Overactivity mutation cancers and example

A

Oncogene. activating cell proliferation. Need one copy of gene mutation. e.g: Philadelphia chromosome in chromic myeloid leukaemia.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Underactivity/loss of function mutations in cancer and example

A

Tumour suppressor gene. Need 2 copies of gene. Inactivate function tumour suppressor gene so no cell proliferation. E.g: p53 protein from the TP53 gene is mutated in over half of all cancers.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

function of proto-oncogenes

A

growth factor, growth factor receptors, singal transduction, nuclear proto-oncogenes and transcription factors.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Mutation in DNA replication error repair

A

linked to colon cancer. small adenoma to large adenoma to carcinoma progression.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Types of anti-cancer drugs targeting DNA synthesis and replication and cell division

A

Antimetabolites e.g. methotrexate, 5-fluorouracil. Antibiotics e.g. Dactomysin. Alkylating agents e.g. temezolomide. Platinum-Coordination Complexes e.g. Cisplatin. Topoisomerase 1 and 2 inhibitors. Tolomerase inhibitors. Mitosis targeting agents e.g. vincristine.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Cell-cycle specific drugs

A

Antimetabolistes, Bleomycin peptide antibiotics, Vinca alkylating agents and Etoposide. Effective for high growth fraction malignancies.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Cell-cycle non specific drugs

A

Alkylating agents. Antibiotics, cisplatin, Nitrosoureas. Effective for high and low growth fraction malignancies.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Examples of antimetabolites and common characteristics

A

Analogous to cell compound interfere with DNA/RNA synethsis in S phase. Methotrexate, 6-mercaptopurine, 5-fluorouracil, Gemcitabine, cytarabine.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Methotrexate mode of action

A

Analogous to folic acid- competitively inhibits dihydrofolate reductase by binding to the enzyme with a higher affinity than the endogenous ligand dihydrofolate.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Pharmacodynamics of Methotrexate

A

Poor BBB crossing as low lipid solubility. Low cell efflux as converted to MTX-polyglutamate. Reduce toxicity with co-adminsitration of Leucovorin an analogue for tetrahydrofolate. Targets S phase.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Use of methotrexate

A

ALL, breast, head, neck and rheumatoid arthritis and other autoimmune diseases.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

Pharmacokinetics of methotrexate

A

IM/IV or intrathecal as poor CNS penetration. Need good patient hydration. Kidney/urine excretion.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

6-Mercaptopurine action

A

Purine antimetabolite drug which has analogous structure to purine. Phosphorylated in cell to active form. Prevents the formation of proper nucleotides for DNA/RNA. Triphosphate form can be incorporated into RNA strand can create non-functional strand.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

Use of 6-mercaptopurine

A

in maintaining remission of ALL

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

Pharmacokinetics of 5-mercaptopurine and resistance

A

Not CNS penetrating. Urine excretion. Resistance due to mutations in gene which creates active form from pro-drug or increasing metabolism.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

5-Fluorouracil action

A

Pro-drug requiring phosphorylation to create ‘fraudulent nucleotide’ with analogous structure to pyrimidine. Reduces DNA precursor molecules by competing for enzyme for dTMP production from DUMP = thymidylate synthetase. S phase acting drug.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Administration,. excretion and other info on 5-Fluorouracil
commonly with MTX. can penetrate to CNS. IV administration. urine excretion.
26
Gemcitabine action
Analogy to deoxycytidine triphosphate nucleotide, incorporated into DNA chain in S phase creating null product.
27
Use of gemcitabine
IV. Advanced metastatic pancreatic cancer. not curative
28
Pharmacology of gemcitabine
Urine excretion. IV infusion. Myelosuppression major ADR. Non-toxic product when deaminated.
29
Cytarabine action
S phase of DNA synthesis. Pyrimidine analogue that is phosphorylated to cytosine arabinoside and is incorporated into strand. Inhibits DNA polymerase.
30
Pharmacology of Cytarabine
IV or intrathecal. Urine excretion. toxic ADR including myelosuppression.
31
Examples of antibiotic anti cancer chemotherapy and common action
Dactinomysin and Anthracyclines such as Doxorubicin, Bleomycin and Daunorubicin. bind to DNA and disrupt function.
32
Dactinomysin action
Intercalates into minor groove of DNA between adjacent G and C nucleotide pairs. Prevents RNA polymerase movement along chain so no synthesis.
33
use of dactinomysin
with MTX. Mostly in paediatric cancers. Resistance can occur with P-glycoprotein.
34
Pharmacokinetics of dactinomysin
Poor CNS penetration. IV. bile and urine excretion.
35
Anthracyclines action
Intercalate into DNA. Oxidase lipids and generate free radicals (superoxides) which damage DNA. Also act to prevent action of DNA breakage repair system by inhibiting topoisomerase 2 which breaks DNA but with drug present can not rejoin the strand. target S and G2 phase.
36
Use of anthracyclines
In combo therapy for breast, lung and leukaemia.
37
Pharmacokinetics of anthracyclines
Bile and urine excretion. poor CNS penetration.
38
Examples of alkylating agents
Mechlorethamine, cyclophosphamide, ifosphamide, carmustine, dacarbazine, temezolomide
39
Action of alkylating agents
Transfer alkyl to DNA giving rise to mutations and cause cross-linking within DNA helix. Most impact in S phase.
40
Pharmacokinetics of alkylating agents
Some need CYP metabolism to active form. Oral or IV. Temozolomide can penetrate to CNS. urine excretion.
41
Use of alkylating agents
combo treatment for solid e.g. brain and lymphatic tumours
42
Examples of platinum coordinatiion complexes
cisplatin, carboplatin, oxaliplatin
43
Action of platinum coordination complexes
Chloride dissociation from complex creates toxic and reactive species. Incooperate platinum into DNA forms intra and inter-genome strand cross links so unable to carry out replication and transcription. G1 and S phase.
44
Use of platinum coordination complexes
Solid tumours: testicular (in combo) or bladder (mono) and ovarian. Oxaliplatin used in colorectal cancer.
45
Pharmacology of platinum coordination complexes
IV. poor CNS penetration. Urine excretion.
46
Examples of topoisomerase 1 inhibitors
Topotecan, irinotecan
47
Action of topoisomerase 1 inhibitors
S phase. Topoisomerase 1= Relax supercoil and separate genome strands, relieve tension. Inhibitors bind to enzyme attached to DNA prevent re-ligation and sealing = broken genome.
48
Use of topoisomerase 1 inhibitors
Topotecan = metastatic ovarian cancer and lung cancer. Irinotecan = colon and rectal cancer in combo with 5-FU and leucovorin.
49
Pharmacology of topoisomerase 1 inhibitors
Irinotecan needs metabolism to active drug in cancer cell. Urine excretion. IV. Myelosuppression with topotecan.
50
Topoisomerase 2 inhibitor examples
Daunorubicin and Doxorubicin. Etoposide and Teniposide
51
Action of topoisomerase 2 inhibitors
Topoisomerase 2 helps DNA relax by forming non-cleavable intermediate complexes. Etoposide and Teniposide bind to transient enzyme and DNA complex = double strand breakage. D and D cataylse the break but not repair of DNA strands. S PHASE
52
Use of topoisomerase 2 inhibitors
Etoposide = in combo with bleomycin and cisplatin for testicular cancer. Teniposide = ALL, glioma and neuroblastoma.
53
Pharmacology of topoisomerase 2 inhibitors and origin
urine excreted. IV and etoposide is oral. Natural compound derivatives.
54
Action of tolomerase
reverse transcription. copies telomeres to prevent shortening of them in replication. Active in malignant but not normal cells. Gives immortality to cancer cells and senescence to normal ones.
55
Example of telomerase inhibitors
Imetelstat (in trial). prevent immortality of cancer cells.
56
Mitosis targetted anti-cancer chemotherapy examples and common action
Vinca alkaloids and Tazanes. Target M phase.
57
Vinca alkaloids Action
Block metaphase. Bind to tubulin and prevent polymerisation into microtubles for organisation of chromosomes. Use in rapidly dividing tumours. Resistance can occur. Also inhibit other functions of microtubules such as axonal transport in neurones and chemotaxis.
58
Taxanes examples
e.g. Paclitaxel and docetaxel
59
Vinca alkaloid examples
Vincristine and vinblastine
60
Taxane action
block metaphase of mitosis. bind to tubulin and promote polymerization but prevent chromosome segregation action.
61
Angiogenesis
Formation of new blood vessels to increase Po2 of tumour. target for anti-cancer drugs
62
Current treatments for cancer and difficulties in chemotherapy for cancer
Surgical, irradiation and chemotherapy. As cancer and human cells are not as dissimilar as microorganisms more difficult to target infected cells.
63
3 genetic components of cancer
Proto-oncogenes mutating to oncogenes. Mutations in tumour suppressor genes. Mutations in DNA repair.
64
Resistance to methotrexate
Not effective for stimulating apoptosis in Melanoma tumours, been shown to be due to poor uptake into the cells possibly via the alpha-folate receptor (2009). resistance is also emerging for use in acute lymphoblastic leukaemia.
65
Use of 5-Fluorouracil
Breast, colorectal, anal, stomach, pancreas, oesophagus, liver, head, neck and bladder carcinomas. Topical administration can be used for skin cancers
66
Use of cytarabine
Acute non-lymphocytic leukaemia
67
Bleomycins
Derivative of anthracyclines. Metal-chelating glyco-peptide antibiotics. Cause chain fragmentation and release free bases. Generate free radicals and destructive oxygen species. Most effective in G2 phase. Little myleopsuppression but can cause pulmonary fibrosis.
68
ADR of alkylating agents
Kill other rapidly dividing cells: decrease gametogenesis, teratogenic, bone marrow suppression, immunosuppressant, nausea and vomiting. Carcinogenic to normal cells = increase risk of non-lymphocytic leukaemia.
69
ADR of platinum compounds
Nephrotoxic. nausea and vomiting (use with serotonin 3 antagonist e.g. ondansetron).
70
Origin of topoisomerase 1 inhibitors
Natural - derive from camptothecin, a compound in a tree.
71
Vinca Alkaloids ADR and origin
ADR of peripheral neuropathy, reversible hair loss and myelosuppression. Natural compounds.
72
Use of taxanes
RX for breast cancer. Use in combo with a platinum compound for advanced ovarian cancer. Also use in non-small cell lung cancers
73
ADR and origin of taxanes
ADR: neutropenia, bone marrow suppression, neurotoxicity, fluid retention. Resistance possible. Semi-synthetic but derivative of yew tree bark compound
74
Natural anticancer chemotherapies
Vinca alkaloids, taxanes, camptothecins, antibiotics and anthracyclines.
75
Example of selective oestrogen receptor modulator and use
Tamoxifen. In hormone-dependent breast cancer.
76
Tamoxifen action
Anti-oestrogen chemotherapy. Competes for intracellular, oestrogen receptor with endogenous oestrogen, binding inhibits the conformational change which initiates transcription of oestrogen-responsive genes, protein produce cause cell growth and proliferation. Therefore the alternative ligand prevents this.
77
Unwanted effects of selective oestrogen receptor modulator
Act as weak oestrogen steroids so could induce opposite effect and stimulate the tumour growth - use limited to 5 years. Hyperplastic changes to endometrium. Thromboembolism.
78
Use of selective oestrogen receptor modulator in post-menopausal women
Use with a gonadotropin releasing hormone analogue e.g. leuprolide to lower oestrogen production.
79
Excretion of Tamoxifen
in faeces.
80
Alternative, non-steroidal option for breast cancer (esp in post-menopausal women)
Aromatase inhibitors
81
Action of aromatase inhibitors
Prevent peripheral synthesis of oestrogen in tissues such as fat and liver. To produce the oestrogen from androgen need the enzyme aromatase.
82
Example of aromatase inhibitors
Anastrozole and Letrozole
83
Treatment of prostate cancer
Antiandrogens. Androgen receptor antagonists. Flutamide, Bicalutamide and Cyproterone Non-steroidal. Bioavailable orally and excreted in the urine.
84
2 examples of Oncogene cancers and potential treatments
Epidermal Growth Factor Receptor (Erb-B)=> cytoplasmic tyrosine kinase inhibitor e.g. Iressa and Tarceva treat occurrence in lung and breast (HER2) cancers. BCR-ABL Fusion Protein=> in chronic myeloid leukaemia. Treat with tyrosine kinase inhibitor e.g Imatinib.
85
Example of tumour suppressor gene cancer and potential treatment
P53 protein is mutated in over 50% of human cancers. It forms a complex with the oncogene MDM2 which degrades the p53 protein. Nutlins bind to MDM2 and release the p53 protein so activate apoptosis of the cell NOT CLINICALLY USED.
86
Oncogene in melanomas and targeted treatment
B-raf - a serine/threonine protein kinase. Inhibitors of b-raf used in melanoma treatment.
87
use of Raf inhibitors
Nexavar - renal cancer also has action on tyrosine kinase. b-raf inhibitors in melanoma.
88
Action of monoclonal antibodies
Prevent binding of growth factors to cell. Initiate an immune response on cell. Conjugated to a toxin or radioisotope.
89
Production of monoclonal antibody
Produced by hybridoma cell cultures which react to a pre-defined, specific target on cancer cells. They are commonly murine or primate and must be humanised to prevent rejection or an immune response on them when administered to patients.
90
New developments in monoclonal antibody production
Create single chain variable region fragments made up of fragments of the antibody not the whole structure. Improve the penetration of the drug.
91
Examples of monoclonal antibodies used
Herceptin/Trastuzumab, Rituximab, Bevacizumab and Cetuximab.
92
Herceptin/Trastuzumab use and action
Target extracellular domain of HER2 in breast cancer reduce proliferation of cells over-expressing this receptor. HER2 has tyrosine kinase activity. Used in progesterone-receptor-tamoxifen-resistant cancers or none-alpha-oestrogen-receptor-expressing cancers
93
Herceptin/Trastuzumab administration, ADR
IV, can be given with other chemotherapy e.g. paclitaxel. ADR = heart failure.
94
Bevacizumab use and action
used in colorectal cancers. restrains the action of vascular endothelial growth factor A. Decrease angiogenesis.
95
Administration of Bevacizumab and ADR
Often with 5-Fluorouracil. IV. ADR = hypertension and interstitial bleeding.
96
Rituximab use and action
Used in Non-hodgkin lymphoma and leukaemia. Fab region of drug binds to CD20 (calcium channel forming) on B lymphocytes and lyses cell. Activates complement factor in immune system.
97
Administration and ADR of Rituximab
IV. can be given in combo with other chemotherapeutics e.g. cyclophosphamide. ADR: hypotension, fever, cardiac pathologies
98
Cetuximab use and action
Targets epithelial growth factor. Used in colorectal cancer treatment
99
Administration and ADRs of Cetuximab
IV in combo with irinotecan. ADR = fever, hypotension.
100
recombinant enzyme example
L-Asparaginase
101
Use of L-asparaginase
Childhood acute lymphocytic anaemia with prednisolone and vincristine. Used in tumours with low asparagine concs
102
Mode of action of l-asparaginase
Neoplastic cells have low asparagine synthetase levels so require host to make sufficient asparagine. The drug depletes the blood levels of asparagine so tumour can not get enough.
103
Two types of interferons
type 1 IFNs with alpha and beta and type 2 IFN with gamma.
104
Action of interferons
Promote apoptosis in cancer cells, stimulate immune recognition of cancer cells.
105
Use of interferons in cancer treatment
IFN-α2a and IFN-α2b - Interferon ALPHA. Used in Melanoma, renal cell carcinoma, Kaposi sarcoma HIV associated.
106
Administration of interferon alpha
IM, sub cut or IV.
107
Interleukins in cancer treatment
Interleukin 2 used in renal cell carcinoma and melanoma. Potentially interleukin-12 too
108
Action of interleukin 2
T lymphocyte growth factor. May act synergistically with IFNα2a.
109
ADR of interleukin 2 use
Hypotension, liver damage. REVERSIBLE. MAX dose of 14 due to tolerance.
110
Action of interleukin 12
Stimulates B and T cells and natural killer cells.
111
What compound does interleukin 12 potentially interact with?
Granulocyte-monocyte colony stimulating factor. Which cam stimulate immune system response to cancer. Used after bone marrow or stem cell transplant.

Chemotherapy (6 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2025 Bold Learning Solutions. Terms and Conditions